Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.3978/j.issn.2218-6751.2016.01.13 http://scihub22266oqcxt.onion/10.3978/j.issn.2218-6751.2016.01.13 C4758961!4758961!26958491     free     free     free Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 213.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Transl+Lung+Cancer+Res 2016 ; 5 (1): 26-38 Nephropedia Template TP {{tp|p=26958491|t=2016. Treatment for small cell lung cancer, where are we now??a review |pdf=|usr=}}{{26958491}} gab.com Text Treatment for small cell lung cancer, where are we now a review JO: Transl Lung Cancer Res http://www.kidney.de/pget.php?&tw=1&pmid=26958491 #FOAvip Small cell lung cancer (SCLC) represents between 13% and 15% of all diagnosed lung cancers worldwide. It is an aggressive neoplasia, with a 5-year mortality of 90% or more. It has historically been classified as limited disease (LD) and extensive disease (ED) in most study protocols. The cornerstone of treatment for any stage of SCLC is etoposide-platinum based chemotherapy; in limited stage (LS), concomitant radiotherapy to thorax and mediastinum. Prophylactic radiotherapy to the central nervous system (CNS) [prophylactic cerebral irradiation (PCI)] has diminished the incidence of brain metastasis as the site for relapse in LD and ED patients, therefore it should be offered to patients with complete response to induction first-line treatment. Regarding second-line treatment, results are more modest and topotecan is accepted as treatment for this scenario offering a modest benefit. Twit Text FOAVip Treatment for small cell lung cancer, where are we now a review ????Transl Lung Cancer Res http://www.kidney.de/pget.php?&tw=1&pmid=26958491 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=26958491 #FOAvip English Wikipedia <ref>{{Cite pmid|26958491}}</ref> Treatment for small cell lung cancer, where are we now??a review #MMPMID26958491 Alvarado-Luna G; Morales-Espinosa D Transl Lung Cancer Res 2016[Feb]; 5 (1): 26-38 PMID26958491show ga Small cell lung cancer (SCLC) represents between 13% and 15% of all diagnosed lung cancers worldwide. It is an aggressive neoplasia, with a 5-year mortality of 90% or more. It has historically been classified as limited disease (LD) and extensive disease (ED) in most study protocols. The cornerstone of treatment for any stage of SCLC is etoposide-platinum based chemotherapy; in limited stage (LS), concomitant radiotherapy to thorax and mediastinum. Prophylactic radiotherapy to the central nervous system (CNS) [prophylactic cerebral irradiation (PCI)] has diminished the incidence of brain metastasis as the site for relapse in LD and ED patients, therefore it should be offered to patients with complete response to induction first-line treatment. Regarding second-line treatment, results are more modest and topotecan is accepted as treatment for this scenario offering a modest benefit. äTreatment for small cell lung cancer, where are we now??a review (epmc).pdf DeepDyve Pubget Overpricing